OncoMatch/Clinical Trials/NCT04216524
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Is NCT04216524 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for blastic plasmacytoid dendritic cell neoplasm.
Treatment: Cyclophosphamide · Cytarabine · Dexamethasone · Doxorubicin · Mercaptopurine · Methotrexate · Methylprednisolone · Prednisone · Rituximab · Tagraxofusp-erzs · Venetoclax · Vincristine — This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Kidney function
Serum creatinine < 1.5x ULN
Liver function
AST and ALT < 2.5x ULN; Total bilirubin < 1.5x ULN (if total bilirubin is > 1.5x but < 3x ULN, and thought to be elevated due to Gilbert's disease or BPDCN, subject may be eligible with PI discussion)
Cardiac function
Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment
Albumin ≥ 3.2 g/dL...Serum creatinine < 1.5x ULN...AST and ALT < 2.5x ULN...Total bilirubin < 1.5x ULN...Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify